Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early entrant to the field of machine learning for cardiology-focused clinical solutions. By leveraging large stores of deidentified data that span full patient journeys from physician notes to medications and imaging files, Anumana develops cardiac AI-based solutions that can glean pertinent disease information from electrocardiogram (ECG)waveforms. The company’s first FDA-cleared cardiac ECG-AI algorithm detects low ejection fraction (LEF), and two additional algorithms for pulmonary hypertension and cardiac amyloidosis are under review.
Anumana Makes Educated Inferences in Heart Failure
Related Articles
Anumana to Showcase AI-Driven Cardiovascular Solutions at AHA and NAPCRG 2024
Company to highlight how its ECG-AI® algorithms enable earlier cardiovascular disease detection{post_date: F d, Y}
AI specialists ink deal with Pfizer to target cardiac amyloidosis
Cardiovascular Business: Anumana, a Massachusetts-based healthcare technology company focused on artificial intelligence (AI), has announced a new multi-year deal with Pfizer focused on improving the identification and diagnosis of cardiac…{post_date: F d, Y}
AI-powered device to identify low LV ejection fraction gains FDA 510(k) clearance
Healio: An AI-powered device to identify low left ventricular ejection fraction in patients at risk for HF gained 510(k) clearance from the FDA.{post_date: F d, Y}
Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for…{post_date: F d, Y}